Manejo de epistaxis en pacientes con terapia antitrombótica

  1. Martín-Bailón, María 1
  2. López-Mesa, Paula 2
  3. Dios-Loureiro, Cristina 2
  1. 1 Hospital Virgen de la Concha
    info

    Hospital Virgen de la Concha

    Zamora, España

    ROR https://ror.org/02bhk3j29

  2. 2 Complexo Hospitalario Universitario de Santiago
    info

    Complexo Hospitalario Universitario de Santiago

    Santiago de Compostela, España

    ROR https://ror.org/00mpdg388

Revista:
Revista ORL

ISSN: 2444-7986,  2444-7986

Ano de publicación: 2021

Volume: 12

Volume: 2

Tipo: Artigo

DOI: 10.14201/ORL.24097 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Outras publicacións en: Revista ORL

Obxectivos de Desenvolvemento Sustentable

Resumo

Introduction and objective: epistaxis is one of the most frequent otorhinolaryngological emergencies. One of its causes is alterations in hemostasis caused by anti-thrombotic therapy. The aim of the study is to determine if there are differences in the management of epistaxis between patients with anti-thrombotic therapy and control patients. Method: retrospective analytical observational study of patients admitted to the Otorhinolaryngology service of a tertiary hospital, between January 2010 and December 2016. Epidemiological, clinical and therapeutic characteristics of the patients have been collected through their electronic medical records and comparative statistical analysis was performed between patients with anti-thrombotic therapy and control patients. Results: a total of 85 patients (74.1% male) were analyzed. Mean age at diagnosis of 66.7 years. 49.4% were undergoing anti-thrombotic therapy. Anterior nasal packing was performed in all patients and posterior nasal packing in 16 patients. 37 patients required endoscopic nasal surgery. Embolization was performed in four patients. In the comparative statistical study, no statistically significant differences were found between both groups in any of the variables analyzed. Discussion and conclusions: the current indications for anti-thrombotic therapy are very broad and therefore it is common to treat epistaxis in this type of patient. Although it has not been clearly demonstrated that anti-thrombotic therapy alone is associated with more serious bleeding, we believe that multidisciplinary management of these patients is essential in order to achieve adequate control of bleeding without the need for more aggressive interventions.

Referencias bibliográficas

  • Boned-Ombuena A, Pérez-Panadés J, López-Maside A, Miralles-Espí M, Guardiola Vilarroig S, Adam Ruiz D, Zurriaga O. Prevalencia de la anticoagulación oral y calidad de su seguimiento en el ámbito de la atención primaria: estudio de la Red Centinela Sanitaria de la Comunitat Valenciana. Aten Primaria. 2017;49(9):534-48.
  • Buchberger AMS, Baumann A, Johnson F, Peters N, Piontek G, Storck K, Pickhard A. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol. 2018;275(8):2035-43.
  • García Callejo FJ, Bécares Martínez C, Calvo González J, Martínez Beneyto P, Marco Sanz M, Marco Algarra J. Epistaxis y dabigatrán, nuevo anticoagulante oral no antagonista de la vitamina K. Acta Otorrinolaringológica Esp. 2014;65(6):346-54.
  • García-Cabo P, Fernández-Vañes L, Pedregal D, Menéndez Del Castro M, Murias E, Vega P, Llorente JL, Rodrigo JP, López F. Manejo de las epistaxis graves yo refractarias. Acta Otorrinolaringol Esp. 2019;70(4):185-91.
  • Glikson E, Chavkin U, Madgar O, Sagiv D, Nakache G, Yakirevitch A, Wolf M, Alon E. Epistaxis in the setting of antithrombotic therapy: a comparison between factor Xa inhibitors, warfarin, and antiplatelet agents. Laryngoscope. 2019; 129(1):119–23.
  • Gomes P, Salvador P, Lombo C, Caselhos S, Fonseca R. Role of age and anticoagulants in recurrent idiopathic epistaxis. Acta Otorrinolaringol Esp. 2019 Sep 11. pii: S0001-6519(19)30119-0. [Epub ahead of print].
  • L’Huillier V, Badet C, Tavernier L. Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135(4):231-5.
  • Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Rev Esp Cardiol Supl. 2013;13(3):33-41.
  • Musgrave KM, Powell J. A systematic review of anti-thrombotic therapy in epistaxis. Rhinology. 2016;54(4):292-391.
  • Navarro JL, Cesar JM, Fernández MA, Fontcuberta J, Reverter JC, Gol-Freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Rev Esp Cardiol. 2007;60(12):1226-32.
  • Ramírez-Sabio J, De Paula-Berneta C, Marco Algarra J. Epistaxis. En: Suárez C, Gil-Carcedo, LM, Marco J, Medina J, Ortega P, Trinidad J. Tratado de Otorrinolaringología y Cirugía de Cabeza y Cuello. 2ª ed. Madrid: Editorial Médica Panamericana; 2007. p. 637-35.
  • Rudmik L, Smith T. Management of intractable spontaneous epistaxis. Am J Rhinol Allergy. 2012; 26(1):55-60.
  • Sauter TC, Hegazy K, Hautz WE, Krummrey G, Ricklin ME, Nagler M, Borner U, Exadaktylos AK. Epistaxis in anticoagulated patients: fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clin Otolaryngol. 2018;43(1):103-8.
  • Send T, Bertlich M, Horlbeck F, Schafigh D, Freytag S, Eichhorn KW, Gräff I, Bootz F, Jakob M. Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin. Int Forum Allergy Rhinol. 2019;9(1):120-124
  • Servizo Galego de Saúde (s.f.). Área Sanitaria de Santiago de Compostela e Barbanza. Entorno. Recuperado el 26 de octubre de 2020 de https://xxisantiago.sergas.gal/DXerais/1008/Poblacion.pdf
  • Smith J, Siddiq S, Dyer C, Rainsbury J, Kim D. Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. J Laryngol Otol. 2011;125(01):38-42.
  • Smith J, Siddiq S, Dyer C, Rainsbury J, Kim D. Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. J Laryngol Otol. 2011;125(1):38-42.
  • Srinivasan V, Patel H, John DG, Worsley A. Warfarin and epistaxis: should warfarin always be discontinued? Clin Otolaryngol Allied Sci. 1997;22(6):542-4.
  • Vaamonde-Lago P, Martín-Martín C, Cajade-Frías J, Mínguez-Beltrán I, Lechuga-García MR, Frade-González C, Bartual-Magro J, Labella-Caballero T. Datos epidemiológicos sobre la epistaxis: estudio hospitalario y revisión de la literatura. Acta Otorrinolaringol. Gallega 2003;4:1-8. ISSN-e 2340-3438.
  • Villwock JA, Jones K. Recent trends in epistaxis management in the United States. 2008-2010. JAMA Otolaryngol Head Neck Surg. 2013;139(12):1279-84.
  • Yau, S. An update on epistaxis. Aust Fam Physician. 2015;44(9):653-6.
Fonte de datos: Dialnet